TABLE 1.
Performance of the IMFA with sera displaying different EBV-specific antibody profiles as determined by EIA
| Serum group (no. of samples) | EBV-specific antibody profile | No. (%) of samples with indicated IMFA result
|
||
|---|---|---|---|---|
| Positive | Weakly positive | Negative | ||
| A (24) | VCA IgG−/IgM+, EBNA-1 IgG− | 17 (70) | 4 (16) | 3 (14) |
| B (23) | VCA IgG+/IgM+, EBNA-1 IgG− | 17 (73) | 4 (17) | 2 (10) |
| C (10) | VCA IgG−/IgM−, EBNA-1 IgG− | 0 (0) | 0 (0) | 10 (100) |
| D (10) | VCA IgG+/IgM−, EBNA-1 IgG+ | 0 (0) | 0 (0) | 10 (100) |
| E (20) | VCA IgG+/IgM+, EBNA-1 IgG+ | 2 (10) | 11 (55) | 7 (35) |
| Fa (15) | 1 (6) | 1 (6) | 13 (88) | |
a
Sera from patients with a mononucleosis-like syndrome owing to CMV, parvovirus B19, or HHV-6. Ten sera lacked EBV-specific antibodies, four sera were VCA IgG+/IgM− and EBNA-1 IgG+, and one serum sample was VCA IgG+/IgM− and EBNA-1 IgG+.